Goldman Sachs
PCVX icon

Goldman Sachs’s Vaxcyte PCVX Stock Holding History

Goldman Sachs’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,000
Closed -$793K – 6334
2025
Q1 		$793K Buy
+21,000
New +$1.68M ﹤0.01% 4860

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's PCVX Position: Q1 2026 in Review

Goldman Sachs increased its Vaxcyte (PCVX) stake by 18% in Q1 2026, buying an estimated $10.7M and bringing the position to 1,275,036 shares worth $74.1M. The position accounts for 0.01% of the portfolio, ranked #1258.

Goldman Sachs first reported a position in PCVX in Q2 2020 and has held it in 23 quarters since. The position peaked at $256M in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Goldman Sachs held 1,275,036 shares of Vaxcyte worth $74.1M as of Q1 2026.
  • Goldman Sachs bought 196,916 Vaxcyte shares in Q1 2026, an estimated $10.7M.
  • Vaxcyte made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1258 holding.
  • Goldman Sachs first reported a position in Vaxcyte in Q2 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Vaxcyte position peaked at $256M in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.